Potent endocannabinoid and anandamide (Cat. No. 1339) analog that activates CB1 receptors in microglia and binds to rat synaptosomal membranes (Ki = 34.4 nM). Cannabimimetic in vivo.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble in ethanol (supplied pre-dissolved in anhydrous ethanol, 5mg/ml)|
Preparing Stock Solutions
The following data is based on the product molecular weight 375.59. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.66 mL||13.31 mL||26.62 mL|
|5 mM||0.53 mL||2.66 mL||5.32 mL|
|10 mM||0.27 mL||1.33 mL||2.66 mL|
|50 mM||0.05 mL||0.27 mL||0.53 mL|
References are publications that support the products' biological activity.
Barg et al (1995) Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur.J.Pharmacol. 287 145 PMID: 8749028
Hanus et al (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J.Med.Chem. 36 3032 PMID: 8411021
Walter et al (2001) Microglial cells produce endocannabinoids and express functional cannabinoid receptors: evidence that docosatetraenylethanolamide (DEA) is an additional endocannabinoid. Soc.Neurosci.Abstr. 634.16 PMID:
If you know of a relevant reference for DEA, please let us know.
View Related Products by Product Action
Keywords: DEA, supplier, Endogenous, CB1, agonists, Cannabinoids, Receptors, cb1r, Docosatetraenylethanolamide, CB1, Receptors, CB1, Receptors, Tocris Bioscience
Citations for DEA
Citations are publications that use Tocris products.
Currently there are no citations for DEA. Do you know of a great paper that uses DEA from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.